S&P 500
(0.80%) 5 277.51 points

Dow Jones
(1.51%) 38 686 points

Nasdaq
(-0.01%) 16 735 points

Oil
(-0.94%) $77.18

Gas
(0.35%) $2.58

Gold
(-0.79%) $2 347.70

Silver
(-3.10%) $30.56

Platinum
(0.63%) $1 044.50

USD/EUR
(-0.17%) $0.921

USD/NOK
(-0.49%) $10.49

USD/GBP
(-0.05%) $0.785

USD/RUB
(0.15%) $90.40

Realtime updates for Hikma Pharmaceuticals PLC [HKMPY]

Exchange: OTC Sector: Healthcare Industry: Drug Manufacturers—Specialty & Generic

Last Updated23 May 2024 @ 12:29

25% discount on Stockinvest.us - Use code: Podcast

1.21% $ 50.39

Live Chart Being Loaded With Signals

Commentary (23 May 2024 @ 12:29):

Hikma Pharmaceuticals PLC develops, manufactures, markets, and sells a range of generic, branded, and in-licensed pharmaceutical products. The company offers its products in solid, semi-solid, liquid, and injectable final dosage forms...

Stats
Today's Volume	4 244.00
Average Volume	479.00
Market Cap	5.59B
Next earnings date	( $0 ) 2024-08-08
Last Dividend	$0.500 ( 2023-08-11 )
Next Dividend	$0 ( N/A )
P/E	29.64
ATR14	$0 (0.00%)

Hikma Pharmaceuticals PLC Correlation

10 Most Positive Correlations

10 Most Negative Correlations

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Hikma Pharmaceuticals PLC Financials

Annual	2023
Revenue:	$2.88B
Gross Profit:	$1.39B (48.35 %)
EPS:	$1.720

FY	2023
Revenue:	$2.88B
Gross Profit:	$1.39B (48.35 %)
EPS:	$1.720

FY	2022
Revenue:	$2.52B
Gross Profit:	$1.24B (49.19 %)
EPS:	$1.680

FY	2021
Revenue:	$2.55B
Gross Profit:	$1.30B (50.96 %)
EPS:	$3.57

Financial Reports:

No articles found.

Hikma Pharmaceuticals PLC Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
$0.380 (N/A)	$0 (N/A)	$0.740 (N/A)	$0 (N/A)	$0.500 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)

Hikma Pharmaceuticals PLC Dividend Information - Ex Dividend Knight

Dividend Sustainability Score: 10.00 - good (100.00%) | Divividend Growth Potential Score: 5.89 - Stable (17.88%)

Very Unsafe

High risk of being cut

Unsafe

Heightened risk of being cut

Borderline

Moderate risk of being cut

Safe

Unlikely to be cut

Very Safe

Very unlikely to be cut

Information

First Dividend	$0.150	2012-04-18
Last Dividend	$0.500	2023-08-11
Next Dividend	$0	N/A
Payout Date	2023-09-25
Next Payout Date	N/A
# dividends	24	--
Total Paid Out	$8.89	--
Avg. Dividend % Per Year	0.00%	--
Score	3.79	--
Div. Sustainability Score	10.00
Div.Growth Potential Score	5.89
Div. Directional Score	8.50	--

Next Divdend (Est)
(2024-06-21)

$0.505 Estimate 7.56 %

Dividend Stability

0.30 Poor

Dividend Score

3.79

Pay Frequency

Semi-Annually

Yearly Payout

Year	Amount	Yield

Dividend Commentary

The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. However, its Dividend Growth Potential Score (DGPS) is only moderate, indicating limited growth potential. In summary, the company provides a promising overall dividend outlook, balancing both sustainability and growth potential.

Top 10 dividend Companies for OTC

Symbol	Title	Last dividend	Frequency	Years Dividend	Yearly Dividend	Score
NPACY	Ex Dividend Knight	2023-08-03	Annually	0	0.00%
CIBN	Ex Dividend Knight	2023-09-14	Quarterly	0	0.00%
UOVEY	Ex Dividend Knight	2023-08-04	Annually	0	0.00%
HLFN	Ex Dividend Knight	2023-07-27	Quarterly	0	0.00%
PSBQ	Ex Dividend Junior	2023-07-06	Annually	0	0.00%
CODYY	Ex Dividend Knight	2023-06-08	Sporadic	0	0.00%
JMHLY	Ex Dividend Knight	2023-08-16	Semi-Annually	0	0.00%
AMIGY	Ex Dividend Knight	2023-09-07	Semi-Annually	0	0.00%
SHZHY	Ex Dividend Knight	2023-09-11	Semi-Annually	0	0.00%
EDNMY	Ex Dividend Junior	2023-06-05	Annually	0	0.00%

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	0.0662	1.500	8.68	10.00	[0 - 0.5]
returnOnAssetsTTM	0.0405	1.200	8.65	10.00	[0 - 0.3]
returnOnEquityTTM	0.0864	1.500	-0.151	-0.227	[0.1 - 1]
payoutRatioTTM	0.723	-1.000	2.77	-2.77	[0 - 1]
currentRatioTTM	1.568	0.800	7.16	5.73	[1 - 3]
quickRatioTTM	0.890	0.800	9.47	7.58	[0.8 - 2.5]
cashRatioTTM	0.153	1.500	-0.261	-0.391	[0.2 - 2]
debtRatioTTM	0.254	-1.500	5.76	-8.64	[0 - 0.6]
interestCoverageTTM	5.46	1.000	9.09	9.09	[3 - 30]
operatingCashFlowPerShareTTM	4.79	2.00	8.40	10.00	[0 - 30]
freeCashFlowPerShareTTM	2.96	2.00	8.52	10.00	[0 - 20]
debtEquityRatioTTM	0.542	-1.500	7.83	-10.00	[0 - 2.5]
grossProfitMarginTTM	0.459	1.000	5.69	5.69	[0.2 - 0.8]
operatingProfitMarginTTM	0.165	1.000	8.70	8.70	[0.1 - 0.6]
cashFlowToDebtRatioTTM	0.444	1.000	8.64	8.64	[0.2 - 2]
assetTurnoverTTM	0.612	0.800	9.25	7.40	[0.5 - 2]
Total Score				11.11

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	29.32	1.000	7.14	0	[1 - 100]
returnOnEquityTTM	0.0864	2.50	-0.0971	-0.227	[0.1 - 1.5]
freeCashFlowPerShareTTM	2.96	2.00	9.01	10.00	[0 - 30]
dividendYielPercentageTTM	2.82	1.500	10.00	0	[0 - 0.4]
operatingCashFlowPerShareTTM	4.79	2.00	8.40	10.00	[0 - 30]
payoutRatioTTM	0.723	1.500	2.77	-2.77	[0 - 1]
pegRatioTTM	4.20	1.500	10.00	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	0.185	1.000	7.88	0	[0.1 - 0.5]
Total Score				5.89

Hikma Pharmaceuticals PLC Options Data

Calls

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Puts

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Hikma Pharmaceuticals PLC

Hikma Pharmaceuticals PLC develops, manufactures, markets, and sells a range of generic, branded, and in-licensed pharmaceutical products. The company offers its products in solid, semi-solid, liquid, and injectable final dosage forms. It operates through three segments: Injectables, Generics, and Branded. The Injectables segment provides generic injectable products primarily for use in hospitals. The Generics segment offers oral and other non-injectable generic products for the retail market. The Branded segment offers branded generics and in-licensed products to retail and hospital markets. The company provides its products in various therapeutic areas, including anti-infective, cardiovascular, central nervous system, diabetes, oncology, pain management, and respiratory. It operates in the United Kingdom, the United States, the Middle East, North Africa, Europe, and internationally. The company was founded in 1978 and is based in London, the United Kingdom.

About Live Signals

The live signals presented on this page help determine when to BUY or SELL NA. The signals have upwards of a 1-minute delay; like all market signals, there is a chance for error or mistakes.

The live trading signals are not definite, and getagraph.com hold no responsibility for any action taken upon these signals, as described in the Terms of Use. The signals are based on a wide range of technical analysis indicators

Investing in the stock market involves risk and the value of your investment can fluctuate. The stock market can be affected by a variety of factors, including economic conditions, company performance, and global events. There is no guarantee of profit and you could lose money. Please consider your financial situation, investment goals, and level of risk tolerance before making any investment decisions. Consult with a financial advisor for personalized advice.

Total Execution Time: 1.5174829959869 seconds
Number of API calls: 2
Number of DB calls: 8